Cargando…

Deep learning for fully-automated nuclear pleomorphism scoring in breast cancer

To guide the choice of treatment, every new breast cancer is assessed for aggressiveness (i.e., graded) by an experienced histopathologist. Typically, this tumor grade consists of three components, one of which is the nuclear pleomorphism score (the extent of abnormalities in the overall appearance...

Descripción completa

Detalles Bibliográficos
Autores principales: Mercan, Caner, Balkenhol, Maschenka, Salgado, Roberto, Sherman, Mark, Vielh, Philippe, Vreuls, Willem, Polónia, António, Horlings, Hugo M., Weichert, Wilko, Carter, Jodi M., Bult, Peter, Christgen, Matthias, Denkert, Carsten, van de Vijver, Koen, Bokhorst, John-Melle, van der Laak, Jeroen, Ciompi, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643392/
https://www.ncbi.nlm.nih.gov/pubmed/36347887
http://dx.doi.org/10.1038/s41523-022-00488-w
_version_ 1784826517016018944
author Mercan, Caner
Balkenhol, Maschenka
Salgado, Roberto
Sherman, Mark
Vielh, Philippe
Vreuls, Willem
Polónia, António
Horlings, Hugo M.
Weichert, Wilko
Carter, Jodi M.
Bult, Peter
Christgen, Matthias
Denkert, Carsten
van de Vijver, Koen
Bokhorst, John-Melle
van der Laak, Jeroen
Ciompi, Francesco
author_facet Mercan, Caner
Balkenhol, Maschenka
Salgado, Roberto
Sherman, Mark
Vielh, Philippe
Vreuls, Willem
Polónia, António
Horlings, Hugo M.
Weichert, Wilko
Carter, Jodi M.
Bult, Peter
Christgen, Matthias
Denkert, Carsten
van de Vijver, Koen
Bokhorst, John-Melle
van der Laak, Jeroen
Ciompi, Francesco
author_sort Mercan, Caner
collection PubMed
description To guide the choice of treatment, every new breast cancer is assessed for aggressiveness (i.e., graded) by an experienced histopathologist. Typically, this tumor grade consists of three components, one of which is the nuclear pleomorphism score (the extent of abnormalities in the overall appearance of tumor nuclei). The degree of nuclear pleomorphism is subjectively classified from 1 to 3, where a score of 1 most closely resembles epithelial cells of normal breast epithelium and 3 shows the greatest abnormalities. Establishing numerical criteria for grading nuclear pleomorphism is challenging, and inter-observer agreement is poor. Therefore, we studied the use of deep learning to develop fully automated nuclear pleomorphism scoring in breast cancer. The reference standard used for training the algorithm consisted of the collective knowledge of an international panel of 10 pathologists on a curated set of regions of interest covering the entire spectrum of tumor morphology in breast cancer. To fully exploit the information provided by the pathologists, a first-of-its-kind deep regression model was trained to yield a continuous scoring rather than limiting the pleomorphism scoring to the standard three-tiered system. Our approach preserves the continuum of nuclear pleomorphism without necessitating a large data set with explicit annotations of tumor nuclei. Once translated to the traditional system, our approach achieves top pathologist-level performance in multiple experiments on regions of interest and whole-slide images, compared to a panel of 10 and 4 pathologists, respectively.
format Online
Article
Text
id pubmed-9643392
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-96433922022-11-15 Deep learning for fully-automated nuclear pleomorphism scoring in breast cancer Mercan, Caner Balkenhol, Maschenka Salgado, Roberto Sherman, Mark Vielh, Philippe Vreuls, Willem Polónia, António Horlings, Hugo M. Weichert, Wilko Carter, Jodi M. Bult, Peter Christgen, Matthias Denkert, Carsten van de Vijver, Koen Bokhorst, John-Melle van der Laak, Jeroen Ciompi, Francesco NPJ Breast Cancer Article To guide the choice of treatment, every new breast cancer is assessed for aggressiveness (i.e., graded) by an experienced histopathologist. Typically, this tumor grade consists of three components, one of which is the nuclear pleomorphism score (the extent of abnormalities in the overall appearance of tumor nuclei). The degree of nuclear pleomorphism is subjectively classified from 1 to 3, where a score of 1 most closely resembles epithelial cells of normal breast epithelium and 3 shows the greatest abnormalities. Establishing numerical criteria for grading nuclear pleomorphism is challenging, and inter-observer agreement is poor. Therefore, we studied the use of deep learning to develop fully automated nuclear pleomorphism scoring in breast cancer. The reference standard used for training the algorithm consisted of the collective knowledge of an international panel of 10 pathologists on a curated set of regions of interest covering the entire spectrum of tumor morphology in breast cancer. To fully exploit the information provided by the pathologists, a first-of-its-kind deep regression model was trained to yield a continuous scoring rather than limiting the pleomorphism scoring to the standard three-tiered system. Our approach preserves the continuum of nuclear pleomorphism without necessitating a large data set with explicit annotations of tumor nuclei. Once translated to the traditional system, our approach achieves top pathologist-level performance in multiple experiments on regions of interest and whole-slide images, compared to a panel of 10 and 4 pathologists, respectively. Nature Publishing Group UK 2022-11-08 /pmc/articles/PMC9643392/ /pubmed/36347887 http://dx.doi.org/10.1038/s41523-022-00488-w Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Article
Mercan, Caner
Balkenhol, Maschenka
Salgado, Roberto
Sherman, Mark
Vielh, Philippe
Vreuls, Willem
Polónia, António
Horlings, Hugo M.
Weichert, Wilko
Carter, Jodi M.
Bult, Peter
Christgen, Matthias
Denkert, Carsten
van de Vijver, Koen
Bokhorst, John-Melle
van der Laak, Jeroen
Ciompi, Francesco
Deep learning for fully-automated nuclear pleomorphism scoring in breast cancer
title Deep learning for fully-automated nuclear pleomorphism scoring in breast cancer
title_full Deep learning for fully-automated nuclear pleomorphism scoring in breast cancer
title_fullStr Deep learning for fully-automated nuclear pleomorphism scoring in breast cancer
title_full_unstemmed Deep learning for fully-automated nuclear pleomorphism scoring in breast cancer
title_short Deep learning for fully-automated nuclear pleomorphism scoring in breast cancer
title_sort deep learning for fully-automated nuclear pleomorphism scoring in breast cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643392/
https://www.ncbi.nlm.nih.gov/pubmed/36347887
http://dx.doi.org/10.1038/s41523-022-00488-w
work_keys_str_mv AT mercancaner deeplearningforfullyautomatednuclearpleomorphismscoringinbreastcancer
AT balkenholmaschenka deeplearningforfullyautomatednuclearpleomorphismscoringinbreastcancer
AT salgadoroberto deeplearningforfullyautomatednuclearpleomorphismscoringinbreastcancer
AT shermanmark deeplearningforfullyautomatednuclearpleomorphismscoringinbreastcancer
AT vielhphilippe deeplearningforfullyautomatednuclearpleomorphismscoringinbreastcancer
AT vreulswillem deeplearningforfullyautomatednuclearpleomorphismscoringinbreastcancer
AT poloniaantonio deeplearningforfullyautomatednuclearpleomorphismscoringinbreastcancer
AT horlingshugom deeplearningforfullyautomatednuclearpleomorphismscoringinbreastcancer
AT weichertwilko deeplearningforfullyautomatednuclearpleomorphismscoringinbreastcancer
AT carterjodim deeplearningforfullyautomatednuclearpleomorphismscoringinbreastcancer
AT bultpeter deeplearningforfullyautomatednuclearpleomorphismscoringinbreastcancer
AT christgenmatthias deeplearningforfullyautomatednuclearpleomorphismscoringinbreastcancer
AT denkertcarsten deeplearningforfullyautomatednuclearpleomorphismscoringinbreastcancer
AT vandevijverkoen deeplearningforfullyautomatednuclearpleomorphismscoringinbreastcancer
AT bokhorstjohnmelle deeplearningforfullyautomatednuclearpleomorphismscoringinbreastcancer
AT vanderlaakjeroen deeplearningforfullyautomatednuclearpleomorphismscoringinbreastcancer
AT ciompifrancesco deeplearningforfullyautomatednuclearpleomorphismscoringinbreastcancer